Novo Nordisk to sell Wegovy in bigger European markets -- Bloomberg
Novo Nordisk $Novo-Nordisk A/S(NVO)$ has resolved production issues that impacted availability of its hugely popular weight loss drug Wegovy (semaglutide) and now says it will launch the drug in larger European markets later this year.
Speaking on Bloomberg Television's "Bloomberg Markets," CEO Lars Fruergaard Jorgensen didn't discuss where exactly those markets might be.
He noted that currently, the drug is available in Norway and Denmark, though patients have to pay out of pocket. He said he is hopeful that discussions with many European markets that cover Novo's (NVO) older obesity drug, Saxenda (liraglutide), will lead to them also reimbursing Wegovy.
Jorgensen added that an additional facility will start Wegovy production in the first half of 2023, with another facility up in the second half.
Production issues last year meant that supplies of Wegovy often couldn't keep up with demand and delayed the further European marketing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comment